Updated:
Ikena Oncology
ImageneBio is a clinical-stage biotechnology company developing therapeutics for patients who have immunological, autoimmune and inflammatory diseases.
Overview
ImageneBio is a clinical-stage biotechnology company developing therapeutics for patients who have immunological, autoimmune and inflammatory diseases.
General information
Location
Region
North America
Country
United States
City
Princeton
Corporate office
Princeton, Boston, United States
Frequently asked questions
How does Ikena Oncology's 2025 reverse merger reshape the entity?
The 2025 transaction separated Ikena's legacy oncology programs into a privately held spin-out and merged the remaining shell with Inmagene Biopharmaceuticals. The surviving Nasdaq company was renamed ImageneBio and now focuses exclusively on immunology via the anti-OX40 antibody IMG-007. This architecture means the entity allocators previously tracked as an oncology play is no longer deploying capital toward cancer therapeutics.
What is IMG-007, and why does the firm consider it differentiated?
IMG-007 is an investigational anti-OX40 monoclonal antibody with an extended half-life. ImageneBio states it inhibits OX40 receptor signaling without depleting T cells — a design claim intended to improve the safety and dosing convenience profile relative to prior OX40-targeting attempts. The company has not published head-to-head clinical data against other OX40 or OX40L agents.
What is ImageneBio's known deployment posture?
ImageneBio is not a fund or an investment vehicle — it is a publicly traded clinical-stage operating company. All internal resources support IMG-007's clinical advancement. A $30 million private placement in April 2026 provided near-term operating runway.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: